Rajnish Wellness Ltd
Incorporated in 2015, Rajnish Wellness Ltd manufactures and sells various ayurvedic medicinal products.[1]
- Market Cap ₹ 41.6 Cr.
- Current Price ₹ 0.41
- High / Low ₹ 1.26 / 0.39
- Stock P/E
- Book Value ₹ 1.01
- Dividend Yield 0.00 %
- ROCE -8.99 %
- ROE -6.74 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 0.41 times its book value
- Debtor days have improved from 137 to 49.7 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 9.16%
- Company has a low return on equity of -1.95% over last 3 years.
- Promoter holding has decreased over last 3 years: -7.08%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 28 | 42 | 14 | 13 | 26 | 26 | 77 | 49 | 142 | 168 | |
| 24 | 24 | 35 | 14 | 17 | 27 | 27 | 75 | 49 | 151 | 177 | |
| Operating Profit | 1 | 3 | 7 | 0 | -3 | -0 | -1 | 2 | 0 | -9 | -8 |
| OPM % | 4.7% | 12% | 16% | 1.0% | -24% | -0.7% | -4.3% | 2.6% | 0.0% | -6% | -5.0% |
| -0 | 1 | 0 | 0 | 4 | 1 | 2 | -0 | 1 | 1 | 1 | |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | -0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 4 | 6 | -1 | 0 | 0 | 1 | 1 | 0 | -8 | -8 |
| Tax % | 33% | 33% | 28% | -2% | 18% | 15% | 27% | 29% | 25% | -25% | |
| 1 | 2 | 4 | -1 | 0 | 0 | 0 | 1 | 0 | -6 | -5 | |
| EPS in Rs | 0.94 | 0.06 | 0.08 | -0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | -0.06 | -0.06 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 60% |
| 3 Years: | 77% |
| TTM: | 357% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -5036% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -11% |
| 3 Years: | -69% |
| 1 Year: | -58% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -1% |
| 3 Years: | -2% |
| Last Year: | -7% |
Balance Sheet
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 3 | 5 | 5 | 5 | 11 | 77 | 77 | 77 | 102 |
| Reserves | 1 | 3 | 18 | 17 | 17 | 12 | 6 | 7 | 7 | 1 |
| 3 | 4 | 5 | 8 | -0 | -0 | 10 | 5 | 0 | 0 | |
| 5 | 8 | 5 | 4 | 13 | 13 | 6 | 17 | 7 | 6 | |
| Total Liabilities | 8 | 18 | 32 | 33 | 35 | 35 | 99 | 106 | 91 | 109 |
| 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 3 | 8 |
| 8 | 18 | 32 | 33 | 35 | 35 | 99 | 106 | 88 | 101 | |
| Total Assets | 8 | 18 | 32 | 33 | 35 | 35 | 99 | 106 | 91 | 109 |
Cash Flows
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2 | -3 | -9 | -7 | 0 | -0 | -62 | 2 | -4 | -9 | |
| -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 9 | -7 | |
| 1 | 3 | 10 | 5 | -0 | 1 | 62 | -2 | -5 | 25 | |
| Net Cash Flow | -0 | -0 | 1 | -1 | 0 | 1 | -1 | -0 | 0 | 9 |
| Free Cash Flow | -2 | -3 | -9 | -7 | 0 | -0 | -62 | 2 | -4 | -9 |
| CFO/OP | -136% | -90% | -118% | -4,650% | -4% | -32% | 5,577% | 105% | -41,900% | 94% |
Ratios
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 182 | 164 | 318 | 460 | 224 | 287 | 160 | 201 | 50 |
| Inventory Days | 152 | 75 | 77 | 48 | 27 | 32 | 59 | 48 | 79 | 35 |
| Days Payable | 121 | 145 | 27 | 56 | 50 | 17 | 55 | 78 | 31 | 7 |
| Cash Conversion Cycle | 90 | 111 | 214 | 310 | 436 | 238 | 290 | 130 | 249 | 77 |
| Working Capital Days | 30 | 102 | 183 | 702 | 791 | 407 | 449 | 305 | 530 | 182 |
| ROCE % | 65% | 37% | 1% | 2% | 3% | 1% | 2% | 1% | -9% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Mix: Sexual Wellness/Branded Medicine % of turnover |
|
|||||||||
| Permanent Employees employees |
||||||||||
| Revenue Mix: Branded Electronics % of turnover |
||||||||||
| Number of Distributors distributors |
||||||||||
| Number of Retailers/Stores stores |
||||||||||
| Number of States of Operation states |
||||||||||
| Number of Super Stockists super stockists |
||||||||||
| Number of C&F Agents C&F agents |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Submission Of Newspaper Clippings Of Un-Audited Financial Results For Quarter Ended 30Th June, 2026
- Submitted newspaper clippings of Q1 FY27 unaudited results; revenue Rs 43.57 crore, net profit Rs 1.90 crore.
- Un-Audited Standalone Financial Results For The Quarter Ended 30Th June, 2026
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today On Thursday The 13Th August, 2026
- Board approved Q1 FY2026-27 unaudited results on 13 Aug 2026; profit rose to Rs 12.30 lakh.
-
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements, 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter And Year Ended 30Th June, 2026 And Other Matters
- Board meeting on 13 Aug 2026 to approve Q1 and FY26 unaudited financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Regulation 74(5) depository compliance certificate filed for quarter ended 30 June 2026.
Business Overview:[1]
RWL is currently engaged in the business of selling various products in the categories ranging from the pharmaceutical products,
consumer durables to ayurvedic personal care products. Its focus area is pharmaceutical, energy revitalization, ayurvedic ethical medicines, personal care products, medicinal sexual enhancement products which are easily
available across the medical counters.